Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

36
Transplantation •Autologous •Syngeneic •Allogeneic •Xenogeneic

Transcript of Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Page 1: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Transplantation

•Autologous

•Syngeneic

•Allogeneic

•Xenogeneic

Page 2: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Routinely performed transplantations:

•Kidney

•Heart

•Liver

•Lungs

•Pancreas

•Small bowel

•Hematopoetic stem cells

Page 3: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Occasionally performed transplantations:

•Hand

•Face

•Larynx (”voice box”)

Page 4: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Main problem in transplantation: Immune system attacks transplant.

Transplantation antigens:

HLA

ABO

Minor histocompatibility antigens

Page 5: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Transplant rejection is an immunological reaction.

Page 6: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Figure 16-2 The genetics of graft rejection. In the illustration, the two different mouse colors represent inbred strains with different MHC haplotypes. Inherited MHC alleles from both parents are codominantly expressed in the skin of an A × B offspring, and therefore these mice are represented by both colors. Syngeneic grafts are not rejected (A). Allografts are always rejected (B). Grafts from a parent of an A × B mating will not be rejected by the offspring (C), but grafts from the offspring will be rejected by either parent (D). These phenomena are due to the fact that MHC gene products are responsible for graft rejection; grafts are rejected only if they express an

MHC type (represented by a color) that is not expressed by the recipient mouse.

Downloaded from: StudentConsult (on 12 March 2008 09:15 AM)

© 2005 Elsevier

The genetics of graft rejection.

Page 7: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.
Page 8: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Direct recognition: Cross-reaction by a normal TCR, which was selected to recognize self MHC plus foreign peptide.

Page 9: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

About 2% of T-cells will react with a cell with foreign MHC molecules:

•One MHC can activate many T-cells

•Allogeneic MHC bind many peptides

•High density of epitopes

•Many memory cells activated

Page 10: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Direct allo-recognition.

MHC

MHC + peptide

Page 11: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Activation of alloreactive T cells.

Page 12: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

MLR

Page 13: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Transplant rejection

•Hyperacute (preformed antibodies)

•Acute (T cell activation)

•Chronic

Page 14: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Immune mechanisms of graft rejection.

Page 15: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Prevention of hyperacute rejection:

ABO typing

Cross-match (recipient serum, donor leukocytes)

Page 16: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Organ transplant recipients need life-long immunosuppression.

Page 17: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Immunosuppression

Page 18: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.
Page 19: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Kidney transplants: Transplantation centres cooperate so that kidneys are given to patients with most similar HLA.

Page 20: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Influence of HLA matching on graft survival.

Page 21: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Once removed from the donor, the kidney must be transplanted within 24-48 hours.

Page 22: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Main complications of immunosuppression:

Increased risk of infection

Increased risk of cancer

Drug toxicity

Page 23: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Xenografts:

Still not possible.Very strong immune reactions.Preformed (natural) antibodies to carbohydrate endothelium antigens – discordant species. For instance man and pig.

Page 24: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Transfusion: the process of transferring whole blood or blood components from one person (donor) to another (recipient).

Blood components: Red blood cells, thrombocytes or plasma.

Page 25: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Three allelic glycosyltransferases ; A, B and O (non-functional) determine the ABO blood type.

Page 26: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

ABO blood group antigens.

Page 27: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Natural antibodies in the ABO system:

A individuals: Anti B

B individuals: Anti A

AB individuals: None

O individuals: Anti A and anti B

Page 28: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Universal donors

Universal recipients

Transfusion of red blood cells

Page 29: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Transfusion of plasma

Page 30: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Rh(D) immunization

(No natural antibodies)

Page 31: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.
Page 32: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

(Bone marrow transplantation)

= Stem cell transplantation

Autologous/Allogeneic

Leukemia, immune deficiency, aplastic anemia

Page 33: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

HLA, but not ABO matching essential. MLR.

Bone marrow registries

Conditioning, harvesting.

Intravenous injection

Aplasia phase – infection risk

Page 34: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Graft versus host disease main complication.

If treatment is successful, permanent immunosuppression is not necessary, but immunodeficiency and infections may be a problem.

Page 35: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

Two mistakes in Abbas’ textbook:

1. Page 374: ”Today, hyperacute rejection by anti-ABO antibodies is extremely rare because all donor and recipient pairs are selected so that they have the same ABO type.”

Identity is not necessary, compatibility is sufficient. For instance, a donor with blood group O can donate a kidney to a recipient with bl.gr. A.

Page 36: Transplantation Autologous Syngeneic Allogeneic Xenogeneic.

2. Page 381: ”HLA matching in renal transplantation is possible because donor kidneys can be stored in organ banks before transplantation until a well-matched recipient can be identified..”

This is just fantasy! Kidney ”organ banks” has never existed. Kidneys must be used within 24-48 hours.